Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology (Internal Medicine) Physician in Rochester, MN
NPI: 1053399246Primary Practice Location
MAYO CLINIC HOSPITAL ROCHESTER
201 W Center St, Rochester, MN
Primary Employer
Mayo Clinic - Mayo Building and Gonda Building
mayoclinic.org
HQ Phone
Get M.D. Patrick's Phone NumberMobile
Get M.D. Patrick's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMN State Medical License
AZ State Medical License
1997
MN State Medical License
1996 - 2026
American Board of Internal Medicine
Hematology
Mayo Clinic Alix School of Medicine - Rochester
college.mayo.edu
Residency • Internal Medicine
1995 - 1998
Fellowship • Hematology and Medical Oncology
1998 - 2001
Heersink School of Medicine - Birmingham
uab.edu
Medical School
Until 1995
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 82 | 101 |
| 2 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 30 | 101 |
| 3 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 15 | 35 |
| 4 | 96365Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | 15 | 15 |
| 5 | 99215Established patient office or other outpatient, visit typically 40 minutes | 15 | 15 |
Authors: Yucai Wang, Jonas Paludo, Arushi Khurana, Patrick Johnston, Roman Kowalchuk, Jennifer Peterson, Jose Villasboas Bisneto, Nabila Bennani, Yi Lin, Stephen Ansell
Journal: J Hematol Oncol
Publication Date: 2022-03-26
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B‐cell non‐Hodgkin lymphoma
Authors: Tait Shanafelt, Grzegorz Nowakowski, David Inwards, Ivana Micallef, Thomas Habermann, Luis Porrata, Clive Zent, Thomas Witzig, Stephen Ansell
Publication Date: 2013-07
Authors: Jonas Paludo, Patrick Johnston, Urshila Durani, Ivana Micallef, Luis Porrata, Svetomir Markovic, Stephen Ansell
Journal: Biomedicines
Publication Date: 2024-08-09
Lead Sponsor: Ono Pharmaceutical Co. Ltd
Intervention / Treatment: DRUG: Tirabrutinib
Lead Sponsor: Miltenyi Biomedicine GmbH
Intervention / Treatment: DRUG: Bendamustine, DRUG: Cyclophosphamide, DRUG: Fludarabine, BIOLOGICAL: zamtocabtagene autoleucel (MB-CART2019.1)
Lead Sponsor: Haihe Biopharma Co., Ltd.
Intervention / Treatment: DRUG: HH2853 Tablets
